Loading...

KLTO KLOTHO NEUROSCIENCES INC US FDA Inspections 8-K Filing

KLTH

KLT

KLOTHO NEUROSCIENCES INC

(KLTO)

2025 8-K

Show Summary

Summary

Pre-Market Approval

Product Expansion

Market Expansion

Asset Acquisitions

Rights Offerings

Reverse Stock Split

Nasdaq Compliance

Nasdaq Compliance Extension

Share Exchange Agreement

Delisting Notice

Capital Structure Change

Convertible Note Agreement

Board Appointment

Agreement Termination

Accountant Change

CEO Employment Agreement

Advisory Board Appointment

Director Resignation

Management Changes

Nasdaq Delisting Notice

Resignation of CFO

Business Combination and Na...

Business Combination Filing

Merger Agreement

Non-Redemption Agreement

Special Meeting of Stockhol...

Adjournment of Special Meeting

Adjournment of Special Meeting

Adjournment of Special Meeting

Adjournment of Special Meeting

Amendment and Charter Amend...

Business Combination Agreem...

Promissory Note Issued

Merger Agreement

Merger of Equals

Entry into Material Definit...

Promissory Note Issued

External Links:

On July 10, 2025, Klotho Neurosciences, Inc. announced that the FDA granted Orphan Drug Designation for its drug KLTO-202, aimed at treating ALS (Lou Gehrig’s Disease). This recognition may enhance the drug's development and market potential for the company.

AI Assistant

KLOTHO NEUROSCIENCES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.